About Invitae (NYSE:NVTA)
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Medical laboratories
Trailing P/E Ratio-2.12
Forward P/E Ratio-2.52
Sales & Book Value
Annual Sales$68.22 million
Price / Sales4.36
Price / CashN/A
Book Value$2.30 per share
Price / Book2.44
EPS (Most Recent Fiscal Year)($2.65)
Return on Equity-124.43%
Return on Assets-68.92%
Invitae (NYSE:NVTA) Frequently Asked Questions
What is Invitae's stock symbol?
Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."
How were Invitae's earnings last quarter?
Invitae Co. (NYSE:NVTA) posted its quarterly earnings results on Monday, February, 12th. The medical research company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.17. The medical research company had revenue of $25.40 million for the quarter, compared to analyst estimates of $24.18 million. Invitae had a negative return on equity of 124.43% and a negative net margin of 180.85%. The firm's revenue for the quarter was up 175.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.69) EPS. View Invitae's Earnings History.
When is Invitae's next earnings date?
What price target have analysts set for NVTA?
4 Wall Street analysts have issued 12 month price targets for Invitae's shares. Their predictions range from $9.00 to $15.00. On average, they expect Invitae's share price to reach $11.00 in the next twelve months. View Analyst Ratings for Invitae.
Who are some of Invitae's key competitors?
Some companies that are related to Invitae include Genomic Health (GHDX), RadNet (RDNT), Natera (NTRA), Enzo Biochem (ENZ), CareDx (CDNA), Veracyte (VCYT), Miragen Therapeutics (MGEN), Celcuity (CELC), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), Biocept (BIOC), OpGen (OPGN) and Cord Blood America (CBAI).
Who are Invitae's key executives?
Invitae's management team includes the folowing people:
- Dr. Randal W. Scott, Exec. Chairman (Age 60)
- Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 44)
- Dr. Robert L. Nussbaum, Chief Medical Officer (Age 68)
- Ms. Shelly D. Guyer, Chief Financial Officer (Age 58)
- Mr. Lee Bendekgey, Chief Operating Officer (Age 60)
When did Invitae IPO?
(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.
Has Invitae been receiving favorable news coverage?
News articles about NVTA stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Invitae earned a coverage optimism score of 0.09 on Accern's scale. They also gave media coverage about the medical research company an impact score of 47.17 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Invitae's major shareholders?
Invitae's stock is owned by many different of retail and institutional investors. Top institutional investors include WELLINGTON MANAGEMENT PORTFOLIOS (DUBLIN) PUBLIC LTD COMPANY (5.23%). Company insiders that own Invitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum and Thomas Brida. View Institutional Ownership Trends for Invitae.
How do I buy shares of Invitae?
Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Invitae's stock price today?
One share of NVTA stock can currently be purchased for approximately $5.64.
How big of a company is Invitae?
Invitae has a market capitalization of $302.32 million and generates $68.22 million in revenue each year. The medical research company earns $-123,380,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. Invitae employs 594 workers across the globe.
How can I contact Invitae?
Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]
MarketBeat Community Rating for Invitae (NVTA)MarketBeat's community ratings are surveys of what our community members think about Invitae and other stocks. Vote "Outperform" if you believe NVTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Invitae (NYSE:NVTA) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Invitae (NYSE NVTA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.70%
Institutional Ownership Percentage: 71.41%
Invitae (NYSE NVTA) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|4/2/2018||Randal W Scott||Insider||Buy||44,444||$4.50||$199,998.00|| |
|3/28/2018||Bros. Advisors Lp Baker||Major Shareholder||Buy||1,111,111||$4.50||$4,999,999.50|| |
|10/10/2017||Patty Dumond||VP||Sell||2,497||$10.00||$24,970.00|| |
|10/9/2017||Patty Dumond||VP||Sell||1,882||$10.00||$18,820.00||52,783|| |
|9/12/2017||Katherine Stueland||Insider||Sell||612||$9.40||$5,752.80||58,570|| |
|2/16/2017||Thomas Brida||General Counsel||Sell||766||$9.69||$7,422.54||24,720|| |
|2/15/2017||E Lee Bendekgey||CFO||Sell||2,098||$9.59||$20,119.82||60,882|| |
|2/15/2017||Patty Dumond||VP||Sell||1,264||$9.55||$12,071.20||55,929|| |
|2/15/2017||Robert L Nussbaum||Insider||Sell||1,686||$9.53||$16,067.58||62,823|| |
|2/15/2017||Thomas Brida||General Counsel||Sell||794||$9.54||$7,574.76||26,280|| |
|11/22/2016||Randal W Scott||Chairman||Buy||66,666||$6.00||$399,996.00||3,506,225|| |
|11/18/2016||Geoffrey Crouse||Director||Buy||15,000||$6.25||$93,750.00||34,259|| |
|11/17/2016||Bros. Advisors Lp Baker||Major Shareholder||Buy||733,333||$6.00||$4,399,998.00|| |
|9/16/2016||Patty Dumond||VP||Sell||1,000||$8.00||$8,000.00||9,812|| |
|8/15/2016||Patty Dumond||VP||Sell||1,000||$8.81||$8,810.00||9,812|| |
|7/14/2016||Patty Dumond||VP||Sell||1,000||$8.79||$8,790.00||9,812|| |
|6/16/2016||Patty Dumond||VP||Sell||1,000||$8.00||$8,000.00||9,812|| |
|5/17/2016||Patty Dumond||VP||Sell||3,221||$8.47||$27,281.87||12,033|| |
|4/14/2016||Patty Dumond||VP||Sell||1,000||$10.50||$10,500.00||9,812|| |
|2/22/2016||Lisa Alderson||Insider||Sell||7,500||$7.64||$57,300.00||31,819|| |
|2/11/2016||Sean E George||COO||Buy||16,950||$6.16||$104,412.00||235,408|| |
|2/18/2015||James E Flynn||Insider||Buy||175,000||$16.00||$2,800,000.00|| |
Invitae (NYSE NVTA) News Headlines
|Invitae Co. (NVTA) Expected to Announce Earnings of -$0.64 Per Share|
www.americanbankingnews.com - April 24 at 3:20 AM
|Comparing Invitae (NVTA) and Its Rivals|
www.americanbankingnews.com - April 21 at 1:04 AM
|Invitae (NVTA) Raised to "Strong-Buy" at Zacks Investment Research|
www.americanbankingnews.com - April 18 at 10:04 AM
|Financial Review: Invitae (NVTA) vs. Its Rivals|
www.americanbankingnews.com - April 17 at 11:10 PM
|Zacks Investment Research Downgrades Invitae (NVTA) to Sell|
www.americanbankingnews.com - April 17 at 9:15 PM
|Invitae (NVTA) vs. Its Competitors Financial Survey|
www.americanbankingnews.com - April 16 at 7:15 AM
|Invitae Co. (NVTA) Given Consensus Rating of "Hold" by Brokerages|
www.americanbankingnews.com - April 15 at 1:27 PM
|Invitae (NVTA) Cut to Sell at BidaskClub|
www.americanbankingnews.com - April 15 at 12:35 PM
|Invitae (NVTA) and Its Peers Head-To-Head Contrast|
www.americanbankingnews.com - April 14 at 7:43 AM
|BidaskClub Upgrades Invitae (NVTA) to "Hold"|
www.americanbankingnews.com - April 13 at 4:23 PM
|Analyzing Invitae (NVTA) & Its Competitors|
www.americanbankingnews.com - April 13 at 8:53 AM
|Head to Head Analysis: Invitae (NVTA) & Its Peers|
www.americanbankingnews.com - April 13 at 1:07 AM
|Financial Comparison: Invitae (NVTA) versus The Competition|
www.americanbankingnews.com - April 11 at 9:20 PM
|Invitae (NVTA) Rating Lowered to Sell at Zacks Investment Research|
www.americanbankingnews.com - April 11 at 9:27 AM
|Invitae (NVTA) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - April 10 at 7:17 PM
|Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic ...|
www.prnewswire.com - April 10 at 4:49 PM
|Invitae (NVTA) & Its Peers Head to Head Survey|
www.americanbankingnews.com - April 9 at 5:13 AM
|Invitae Co. (NVTA) Expected to Post Quarterly Sales of $25.82 Million|
www.americanbankingnews.com - April 9 at 4:06 AM
|BidaskClub Upgrades Invitae (NVTA) to Hold|
www.americanbankingnews.com - April 8 at 9:07 AM
|Genomic Health (GHDX) and Invitae (NVTA) Head-To-Head Review|
www.americanbankingnews.com - April 7 at 3:16 PM
|Invitae (NVTA) and Its Rivals Critical Comparison|
www.americanbankingnews.com - April 7 at 7:31 AM
|Zacks: Brokerages Expect Invitae Co. (NVTA) Will Announce Earnings of -$0.64 Per Share|
www.americanbankingnews.com - April 7 at 5:58 AM
|Zacks Investment Research Downgrades Invitae (NVTA) to Hold|
www.americanbankingnews.com - April 7 at 12:39 AM
|Critical Review: ELEKTA (EKTAY) vs. Invitae (NVTA)|
www.americanbankingnews.com - April 5 at 9:18 AM
|Invitae (NVTA) Rating Lowered to Hold at BidaskClub|
www.americanbankingnews.com - April 4 at 11:58 PM
|Invitae (NVTA) and Its Competitors Financial Survey|
www.americanbankingnews.com - April 4 at 11:12 PM
|Critical Review: InVitae (NVTA) & The Competition|
www.americanbankingnews.com - April 3 at 9:23 PM
|InVitae Corp (NVTA) Insider Randal W. Scott Acquires 44,444 Shares|
www.americanbankingnews.com - April 2 at 10:20 PM
|BidaskClub Lowers InVitae (NVTA) to Sell|
www.americanbankingnews.com - April 2 at 10:13 AM
|Form 4 BAKER FELIX For: Mar 28 Filed by: Invitae Corp|
www.streetinsider.com - March 31 at 8:56 AM
|InVitae Corp (NVTA) Major Shareholder Bros. Advisors Lp Baker Acquires 1,111,111 Shares|
www.americanbankingnews.com - March 29 at 4:20 PM
|Here's Why Invitae Stock Dropped as Much as 19.6% Today|
www.fool.com - March 29 at 9:20 AM
|Here's Why Invitae Stock Dropped as Much as 19.6% Today|
finance.yahoo.com - March 28 at 4:46 PM
|Mid-Afternoon Market Update: NASDAQ Down Over 100 Points; Invitae Shares Fall Following Announcement Of $50M ...|
www.nasdaq.com - March 27 at 4:55 PM
|This Explains Why Invitae Is Sinking Today|
finance.yahoo.com - March 27 at 4:55 PM
|Invitae Corporation (NYSE:NVTA): When Will It Breakeven?|
finance.yahoo.com - March 27 at 4:55 PM
|10 Stocks To Watch For March 27, 2018|
www.benzinga.com - March 27 at 8:56 AM
|Zacks: Brokerages Anticipate InVitae Corp (NVTA) Will Post Quarterly Sales of $25.82 Million|
www.americanbankingnews.com - March 23 at 8:28 AM
|Invitae expands network of patients in rare and ultra-rare diseases|
finance.yahoo.com - March 22 at 9:06 AM
|InVitae Corp (NVTA) Given Consensus Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - March 21 at 3:56 PM
|Zacks: Analysts Expect InVitae Corp (NVTA) to Post -$0.64 Earnings Per Share|
www.americanbankingnews.com - March 21 at 5:18 AM
|Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic information|
finance.yahoo.com - March 16 at 9:50 AM
|BRIEF-Invitae Says Goal Of 1 Mln Customers, $500 Mln In Revenue In 2020|
www.reuters.com - March 13 at 10:41 AM
|Technical Perspectives on Medical Research Stocks -- Bruker, DexCom, Invitae, and IQVIA|
www.bizjournals.com - March 7 at 9:37 AM
|What Are Analysts Saying About Invitae Corporation’s (NYSE:NVTA) Future?|
finance.yahoo.com - March 6 at 4:47 PM
|$25.82 Million in Sales Expected for InVitae Corp (NVTA) This Quarter|
www.americanbankingnews.com - March 6 at 10:47 AM
|Invitae expands existing credit facility to provide up to $40.0 million in available growth capital|
finance.yahoo.com - February 27 at 4:55 PM
|Invitae to present at the Cowen and Company 38th Annual Health Care Conference|
finance.yahoo.com - February 26 at 9:25 AM
|ARK Investment Management LLC Buys 643,860 Shares of InVitae Corp (NVTA)|
www.americanbankingnews.com - February 26 at 5:12 AM
|InVitae Corp (NVTA) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - February 24 at 3:42 PM
Invitae (NYSE:NVTA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Invitae (NYSE:NVTA) Income Statement, Balance Sheet and Cash Flow Statement
Invitae (NYSE NVTA) Stock Chart for Tuesday, April, 24, 2018